Syndax Announces Participation in Upcoming Investor Conferences

About this update from Syndax Pharmaceuticals, Inc.

[{"type":"image","alt":"Syndax Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Syndax Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/5775244779f64273f7aa7061ff889f13"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zJ7cvDXsKBaXTzG8sMjOYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/5775244779f64273f7aa7061ff889f13","width":300,"height":80},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zJ7cvDXsKBaXTzG8sMjOYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/5775244779f64273f7aa7061ff889f13","width":300,"height":80}},"lazy":false},{"type":"text","content":"NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:","length":346,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TD Cowen 7th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 27, 2026, at 1:00 p.m. ET.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Jefferies Global Healthcare Conference in New York, NY with a fireside chat on Thursday, June 4, 2026, at 9:20 a.m. ET.","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Monday, June 8, 2026, at 2:00 p.m. ET.","length":142,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":381,"olType":false},{"type":"text","content":"A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.","length":184,"tagName":"p"},{"type":"text","content":"About Syndax","length":12,"tagName":"p"},{"type":"text","content":"Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibit...

More updates from Syndax Pharmaceuticals, Inc.